Cambridge, MA-based Forma Therapeutics has formed a partnership with the Leukemia & Lymphoma Society of White Plains, NY, to discover drugs for immune cell cancers, according to a press release. No financial details were revealed. The partnership will focus on blocking a protein known as “Bcl-6,” which plays a role many lymphomas. Forma has been on a roll on the fund-raising and partnership fronts, having revealed more than $50 million in funding last year as well as a drug-discovery deal with Lexington, MA-based Cubist Pharmaceuticals (NASDAQ:[[ticker:CBST]]).
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
